Gritstone Oncology Revenue and Competitors

Claim your profile

Location

$396M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gritstone Oncology's estimated annual revenue is currently $46.5M per year.(i)
  • Gritstone Oncology received $92.7M in venture funding in September 2017.
  • Gritstone Oncology's estimated revenue per employee is $176,136
  • Gritstone Oncology's total funding is $396M.
  • Gritstone Oncology's current valuation is $424.9M. (January 2022)

Employee Data

  • Gritstone Oncology has 264 Employees.(i)
  • Gritstone Oncology grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.8M763%$3MN/A
#2
$1.2M6N/AN/AN/A
#3
$20.9M10430%$176.6MN/A
#4
$39060M6975615%$30 b$234.4B
#5
$108.1M538N/AN/AN/A
#6
$24.7M155N/AN/AN/A
#7
$124.8M93834%$567.2M$2.2B
#8
$1.1M13N/AN/AN/A
#9
$0.8M5N/AN/AN/A
#10
$2360M388710%$22.5M$10.7B
#11
$10.1M65N/AN/AN/A
#12
$275.4M122011%N/A$4.4B
#13
$7M45N/AN/AN/A
#14
$21.6M88-6%N/AN/A
#15
$0.1M4N/AN/AN/A
#16
$2.6M26N/AN/AN/A
#17
$71.6M462N/AN/AN/A
#18
$6.8M44N/AN/AN/A
#19
$0.4M8N/AN/AN/A
#20
$188.8M930N/AN/AN/A

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$396M

Total Funding

264

Number of Employees

$46.5M

Revenue (est)

14%

Employee Growth %

$424.9M

Valuation

N/A

Accelerator

Gritstone Oncology News

2022-04-20 - Neoantigen Cancer Vaccine Market Size, Scope And Forecast ...

... Agenus, Roche, Nouscom, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, BioNTech, ISA Pharmaceutical, Vaccibody.

2022-04-19 - MarketsandMarkets Biopharma Series - Healthcare Trends, Innovations & Disruptions Under One Roof!

5TH ANNUAL MARKETSANDMARKETS NEXT-GEN IMMUNO-ONCOLOGY CONFERENCE ... Director, Molecular Biology and Sequencing, Gritstone Oncology, Inc

2022-04-13 - Gritstone Oncology (GRTS) Delivers Presentations Supporting ...

Gritstone Oncology (GRTS) Delivers Presentations Supporting Expertise in Neoantigen Vaccine Design and Delivery. April 12, 2022 4:35 PM.

2019-09-08 - Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlights

12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.2M26476%$132M
#2
$52.5M265N/AN/A
#3
$79M26611%N/A
#4
$55.6M281N/AN/A
#5
$24.1M2951%$1.5B

Gritstone Oncology Funding

DateAmountRoundLead InvestorsReference
2015-10-21$102.0MAVersant VenturesArticle
2017-09-08$92.7MUndisclosedLilly Asia VenturesArticle